Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Thorn

Showing results (71-80 of 95) with videos related to

Pageof 10
Sort By:
Pharmacogenetics and Genomics|August 22, 2013
PharmGKB summary: tamoxifen pathway, pharmacokineticsDaniel J Klein, Caroline F Thorn, Zeruesenay Desta, et al.
Pharmacogenetics and Genomics|November 5, 2010
Doxorubicin pathways: pharmacodynamics and adverse effectsCaroline F Thorn, Connie Oshiro, Sharon Marsh, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology|June 24, 2004
A common ABCC2 promoter polymorphism is not a determinant of the risk of spina bifidaLiselotte E Jensen, Amelia M Wall, Michelle Cook, et al.
Pharmacogenetics and Genomics|July 9, 2011
PharmGKB summary: carbamazepine pathwayCaroline F Thorn, Susan G Leckband, John Kelsoe, et al.
Clinical Pharmacology and Therapeutics|December 13, 2012
Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosingM S Hershfield, J T Callaghan, W Tassaneeyakul, et al.
Pharmacogenetics and Genomics|October 27, 2011
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19Stuart A Scott, Katrin Sangkuhl, Alan R Shuldiner, et al.
Clinical Pharmacology and Therapeutics|August 31, 2013
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosingK E Caudle, C F Thorn, T E Klein, et al.
Pharmacogenetics and Genomics|December 16, 2014
PharmGKB summary: ibuprofen pathwaysLiudmila L Mazaleuskaya, Katherine N Theken, Li Gong, et al.
Pharmacogenomics|February 28, 2007
Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivityCarmel Kealey, Zhen Chen, Jason Christie, et al.
Pharmacogenetics and Genomics|August 28, 2014
PharmGKB summary: gemcitabine pathwayMaria L Alvarellos, Jatinder Lamba, Katrin Sangkuhl, et al.
Pageof 10

Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Pharmacogenetics and Genomics|August 22, 2013
PharmGKB summary: tamoxifen pathway, pharmacokineticsDaniel J Klein, Caroline F Thorn, Zeruesenay Desta, et al.
Pharmacogenetics and Genomics|November 5, 2010
Doxorubicin pathways: pharmacodynamics and adverse effectsCaroline F Thorn, Connie Oshiro, Sharon Marsh, et al.
Birth Defects Research. Part A, Clinical and Molecular Teratology|June 24, 2004
A common ABCC2 promoter polymorphism is not a determinant of the risk of spina bifidaLiselotte E Jensen, Amelia M Wall, Michelle Cook, et al.
Pharmacogenetics and Genomics|July 9, 2011
PharmGKB summary: carbamazepine pathwayCaroline F Thorn, Susan G Leckband, John Kelsoe, et al.
Clinical Pharmacology and Therapeutics|December 13, 2012
Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosingM S Hershfield, J T Callaghan, W Tassaneeyakul, et al.
Pharmacogenetics and Genomics|October 27, 2011
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19Stuart A Scott, Katrin Sangkuhl, Alan R Shuldiner, et al.
Clinical Pharmacology and Therapeutics|August 31, 2013
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosingK E Caudle, C F Thorn, T E Klein, et al.
Pharmacogenetics and Genomics|December 16, 2014
PharmGKB summary: ibuprofen pathwaysLiudmila L Mazaleuskaya, Katherine N Theken, Li Gong, et al.
Pharmacogenomics|February 28, 2007
Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivityCarmel Kealey, Zhen Chen, Jason Christie, et al.
Pharmacogenetics and Genomics|August 28, 2014
PharmGKB summary: gemcitabine pathwayMaria L Alvarellos, Jatinder Lamba, Katrin Sangkuhl, et al.
Pageof 10